Skip Navigation


Human Molecular Genetics Advance Access originally published online on April 4, 2007
Human Molecular Genetics 2007 16(11):1293-1306; doi:10.1093/hmg/ddm078
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/11/1293    most recent
ddm078v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sadri-Vakili, G.
Right arrow Articles by Cha, J.-H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sadri-Vakili, G.
Right arrow Articles by Cha, J.-H. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models

Ghazaleh Sadri-Vakili1, Bérengère Bouzou2, Caroline L. Benn1, Mee-Ohk Kim1, Prianka Chawla1, Ryan P. Overland1, Kelly E. Glajch1, Eva Xia1, Zhihua Qiu1, Steven M. Hersch1, Timothy W. Clark2, George J. Yohrling3 and Jang-Ho J. Cha1,*

1 Department of Neurology, 2 Center for Interdisciplinary Informatics, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, B114-2000, 114 16th Street, Charlestown, MA 02129-4404, USA and 3 Johnson & Johnson Pharmaceuticals, Research & Development, L.L.C., Welsh & McKean Roads, PO Box 776, Spring House, PA 19477, USA

* To whom correspondence should be addressed. Tel: +1 6177241481; Fax: +1 6177241480; Email: cha{at}helix.mgh.harvard.edu

Received February 22, 2007; Accepted March 20, 2007

Transcriptional dysregulation plays a major role in the pathology of Huntington's disease (HD). However, the mechanisms causing selective downregulation of genes remain unknown. Histones regulate chromatin structure and thereby control gene expression; recent studies have demonstrated a therapeutic role for histone deacetylase (HDAC) inhibitors in polyglutamine diseases. This study demonstrates that despite no change in overall acetylated histone levels, histone H3 is hypo-acetylated at promoters of downregulated genes in R6/2 mice, ST14a and STHdh cells, as demonstrated by in vivo chromatin immunoprecipitation. In addition, HDAC inhibitor treatment increases association of acetylated histones with downregulated genes and corrects mRNA abnormalities. In contrast, there is a decrease in mRNA levels in wild-type cells following treatment with a histone acetyltransferase inhibitor. Although changes in histone acetylation correlate with decreased gene expression, histone hypo-acetylation may be a late event, as no hypo-acetylation is observed in 4-week-old R6/2 mice. Nevertheless, treatment with HDAC inhibitors corrects mRNA abnormalities through modification of histone proteins and may prove to be of therapeutic value in HD.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. Pennuto, I. Palazzolo, and A. Poletti
Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity
Hum. Mol. Genet., April 15, 2009; 18(R1): R40 - R47.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
C. L. Benn, T. Sun, G. Sadri-Vakili, K. N. McFarland, D. P. DiRocco, G. J. Yohrling, T. W. Clark, B. Bouzou, and J.-H. J. Cha
Huntingtin Modulates Transcription, Occupies Gene Promoters In Vivo, and Binds Directly to DNA in a Polyglutamine-Dependent Manner
J. Neurosci., October 15, 2008; 28(42): 10720 - 10733.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. A. Thomas, G. Coppola, P. A. Desplats, B. Tang, E. Soragni, R. Burnett, F. Gao, K. M. Fitzgerald, J. F. Borok, D. Herman, et al.
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice
PNAS, October 7, 2008; 105(40): 15564 - 15569.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M.-O. Kim, P. Chawla, R. P. Overland, E. Xia, G. Sadri-Vakili, and J.-H. J. Cha
Altered Histone Monoubiquitylation Mediated by Mutant Huntingtin Induces Transcriptional Dysregulation
J. Neurosci., April 9, 2008; 28(15): 3947 - 3957.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
E. Roze, S. Betuing, C. Deyts, E. Marcon, K. Brami-Cherrier, C. Pages, S. Humbert, K. Merienne, and J. Caboche
Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death
FASEB J, April 1, 2008; 22(4): 1083 - 1093.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.